The development of monoclonal antibodies for the therapy of cancer

Roula A. Farah, Birgitta Clinchy, Larry Herrera, Ellen S. Vitetta

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Monoclonal antibodies (Mabs) were first decribed by Kohler and Milstein in 1975. Not only did this discovery lead to a Nobel prize, but it created an enormous scientific field that has now become a multimillion dollar industry. Mabs made the transition from laboratory reagents to clinical diagnostics very quickly. However, their development as therapeutic agents was, as predicted, more costly and time-consuming. Indeed, clinicians and scientists were required to learn a new set of rules for using these large, immunogenic, targeted agents in humans. Nevertheless, in 1997 the first Mab was licensed in the U.S. and several others will soon follow. In this review, we discuss Mab-based strategies for the treatment of cancer. We compare native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. The rationale for their development, their advantages, their in vitro and in vivo performance, and their clinical usefulness are discussed.

Original languageEnglish (US)
Pages (from-to)321-356
Number of pages36
JournalCritical Reviews in Eukaryotic Gene Expression
Volume8
Issue number3-4
StatePublished - 1998

Fingerprint

Monoclonal Antibodies
Bispecific Antibodies
Immunoconjugates
Nobel Prize
Neoplasms
Industry
Antibodies
Therapeutics
In Vitro Techniques

Keywords

  • Cancer therapy
  • Immunoconjugates
  • Immunotherapy
  • Monoclonal antibodies
  • Recombinant antibodies

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

The development of monoclonal antibodies for the therapy of cancer. / Farah, Roula A.; Clinchy, Birgitta; Herrera, Larry; Vitetta, Ellen S.

In: Critical Reviews in Eukaryotic Gene Expression, Vol. 8, No. 3-4, 1998, p. 321-356.

Research output: Contribution to journalArticle

Farah, Roula A. ; Clinchy, Birgitta ; Herrera, Larry ; Vitetta, Ellen S. / The development of monoclonal antibodies for the therapy of cancer. In: Critical Reviews in Eukaryotic Gene Expression. 1998 ; Vol. 8, No. 3-4. pp. 321-356.
@article{6c16ad08785a4a57a0af94fb246b7f5f,
title = "The development of monoclonal antibodies for the therapy of cancer",
abstract = "Monoclonal antibodies (Mabs) were first decribed by Kohler and Milstein in 1975. Not only did this discovery lead to a Nobel prize, but it created an enormous scientific field that has now become a multimillion dollar industry. Mabs made the transition from laboratory reagents to clinical diagnostics very quickly. However, their development as therapeutic agents was, as predicted, more costly and time-consuming. Indeed, clinicians and scientists were required to learn a new set of rules for using these large, immunogenic, targeted agents in humans. Nevertheless, in 1997 the first Mab was licensed in the U.S. and several others will soon follow. In this review, we discuss Mab-based strategies for the treatment of cancer. We compare native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. The rationale for their development, their advantages, their in vitro and in vivo performance, and their clinical usefulness are discussed.",
keywords = "Cancer therapy, Immunoconjugates, Immunotherapy, Monoclonal antibodies, Recombinant antibodies",
author = "Farah, {Roula A.} and Birgitta Clinchy and Larry Herrera and Vitetta, {Ellen S.}",
year = "1998",
language = "English (US)",
volume = "8",
pages = "321--356",
journal = "Critical Reviews in Eukaryotic Gene Expression",
issn = "1045-4403",
publisher = "Begell House Inc.",
number = "3-4",

}

TY - JOUR

T1 - The development of monoclonal antibodies for the therapy of cancer

AU - Farah, Roula A.

AU - Clinchy, Birgitta

AU - Herrera, Larry

AU - Vitetta, Ellen S.

PY - 1998

Y1 - 1998

N2 - Monoclonal antibodies (Mabs) were first decribed by Kohler and Milstein in 1975. Not only did this discovery lead to a Nobel prize, but it created an enormous scientific field that has now become a multimillion dollar industry. Mabs made the transition from laboratory reagents to clinical diagnostics very quickly. However, their development as therapeutic agents was, as predicted, more costly and time-consuming. Indeed, clinicians and scientists were required to learn a new set of rules for using these large, immunogenic, targeted agents in humans. Nevertheless, in 1997 the first Mab was licensed in the U.S. and several others will soon follow. In this review, we discuss Mab-based strategies for the treatment of cancer. We compare native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. The rationale for their development, their advantages, their in vitro and in vivo performance, and their clinical usefulness are discussed.

AB - Monoclonal antibodies (Mabs) were first decribed by Kohler and Milstein in 1975. Not only did this discovery lead to a Nobel prize, but it created an enormous scientific field that has now become a multimillion dollar industry. Mabs made the transition from laboratory reagents to clinical diagnostics very quickly. However, their development as therapeutic agents was, as predicted, more costly and time-consuming. Indeed, clinicians and scientists were required to learn a new set of rules for using these large, immunogenic, targeted agents in humans. Nevertheless, in 1997 the first Mab was licensed in the U.S. and several others will soon follow. In this review, we discuss Mab-based strategies for the treatment of cancer. We compare native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. The rationale for their development, their advantages, their in vitro and in vivo performance, and their clinical usefulness are discussed.

KW - Cancer therapy

KW - Immunoconjugates

KW - Immunotherapy

KW - Monoclonal antibodies

KW - Recombinant antibodies

UR - http://www.scopus.com/inward/record.url?scp=0032471590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032471590&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 321

EP - 356

JO - Critical Reviews in Eukaryotic Gene Expression

JF - Critical Reviews in Eukaryotic Gene Expression

SN - 1045-4403

IS - 3-4

ER -